Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

American Journal of Health-System Pharmacy Pub Date : 2025-04-08 DOI:10.1093/ajhp/zxaf045

Thelma Barber, Joshua J Neumiller, Michelle A Fravel, Robert L Page, Katherine R Tuttle

{"title":"Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease.","authors":"Thelma Barber, Joshua J Neumiller, Michelle A Fravel, Robert L Page, Katherine R Tuttle","doi":"10.1093/ajhp/zxaf045","DOIUrl":null,"url":null,"abstract":"Purpose: An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team.Summary: Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care-inclusive of the person with chronic kidney disease-have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.Conclusion: As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxaf045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team.

Summary: Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care-inclusive of the person with chronic kidney disease-have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.

Conclusion: As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.

查看原文本刊更多论文

使用指南指导的药物治疗来改善慢性肾脏疾病患者的肾脏和心血管预后

目的：目前在美国估计有3700万人患有慢性肾病，这使他们面临肾脏疾病进展、心血管疾病和死亡的风险增加。本综述讨论了目前慢性肾病患者的标准护理管理，确定了护理中的关键差距，并简要强调了药剂师作为多学科护理团队成员如何解决护理差距。摘要：慢性肾病患者的指导医学治疗的最新进展，包括钠-葡萄糖共转运体、胰高血糖素样肽-1受体激动剂和非甾体类矿皮质激素受体拮抗剂，可以显着改善心血管-肾脏代谢护理和预后。不幸的是，在筛查、诊断和实施推荐疗法方面的差距仍然存在。以团队为基础的护理模式——包括慢性肾病患者——有可能通过解决目前护理方面的差距，显著改善慢性肾病患者的护理和结果。结论：作为多学科护理团队的成员，药剂师可以在解决当前护理差距方面发挥关键作用，包括优化使用指南指导的药物治疗，用于慢性肾脏疾病患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Health-System Pharmacy 医学-药学

CiteScore

2.90

自引率

18.50%

发文量

341

审稿时长

3-8 weeks

期刊介绍： The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.